Administrative Core

行政核心

• 批准号: 10473853
• 负责人: HAL E. BROXMEYER
• 金额: $ 7.51万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10473853
• 关键词: Adopted; Adult; Area; Basic Science; Biochemical; Biology; Biomedical Research; Blood Vessels; Bone Marrow Diseases; Cell Cycle Regulation; Cell Therapy; Cells; Childhood; Clinic; Clinical; Clinical Research; Collaborations; Country; Developmental Biology; Discipline; Disease; Elements; Ensure; Epigenetic Process; Expenditure; Fostering; Funding; Funding Mechanisms; Future; Gene Transfer; Goals; Growth Factor; Health Benefit; Hematology; Hematopoiesis; Hematopoietic; Hematopoietic System; Hematopoietic stem cells; Hereditary Disease; Homing; Human; Immunology; Indiana; Investigation; Medical Genetics; Medicine; Microbiology; Modality; Molecular; Molecular Biology; Molecular Genetics; Mus; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Malignant; Orthopedic Surgery; Pediatrics; Policies; Regulation; Research; Research Personnel; Scientist; Services; Source; Stem cell transplant; Technology; Training Programs; Translations; Transplantation; Travel; United States National Institutes of Health; Universities; Work; base; chemokine; clinical efficacy; cytokine; experience; genetic approach; hematopoietic cell transplantation; hematopoietic tissue; improved; innovative technologies; insight; interest; medical schools; member; migration; progenitor; programs; self-renewal; stem; stem cell biology; stem cells

Project Summary The central theme of the Indiana University (IU) Cooperative Center of Excellence in Hematology (CCEH) is the regulation of nonmalignant human and murine hematopoiesis at the level of hematopoietic stem (HSC) and progenitor (HPC) cells, cytokines, chemokines, growth factors, and the microenvironment. This was the focus of the IU-CCEH during the last funding period. We continue to pursue this hefty goal, as we realize that there is still much more that needs to be rigorously defined in these areas. The goals of the investigations of members of this center are to leverage different components of the hematopoietic system to improve and advance clinical utility and efficacy of HSC/HPC-based therapies. Treatment of inherited disorders of bone marrow- derived cells can be achieved by both cellular and genetic approaches that are applicable to many diseases and disorders. However, successful application of these modalities requires a deeper understanding of the cellular, molecular, biochemical HSC and HPC regulation and hematopoietic parameters impacting their efficient use in transplantation such as homing, cell cycle regulation, self-renewal, epigenetics, and the status of the hematopoietic niche. The proposed IU-CCEH brings together the active participation of 25 members who are well funded by the NIH, DoD, or the VA. These investigators are highly interactive with diverse and complementary expertise in hematopoiesis and HSC biology and other disciplines that impact directly or indirectly on multiple components of the hematopoietic system. The IU-CCEH proposes the establishment of 3 biomedical research cores focused on bringing state-of-the-art technologies that advance the work of the members of this center, other similar CCEH centers across the country, and qualified investigators nationwide who do not belong to any NIDDK-funded CCEH. In addition, the IU-CCEH will have an Enrichment Program Core tasked with establishing training programs for young and future scientists interested in nonmalignant hematology research. The specific aims of the IU-CCEH are: 1) Establish, operate, and administer three vital biomedical cores providing essential services to investigators at the IUSM and others outside the IUSM who are involved in the highest quality nonmalignant basic and clinical research in HSC/HPC biology. 2) Establish, operate and administer an Enrichment Program to support, promote and enhance the research of young investigators in the area of nonmalignant HSC regulation and clinical utility of HSC. 3) Actively participate in the implementation of a Partner Pilot and Feasibility funding mechanism organized by all NIDDK-sponsored CCEH centers across the U.S.A. 4) Coordinate fiscal management of the cores of the proposed application. 5) Work closely and cooperate with other CCEH centers nationwide to adopt and implement policies, funding mechanisms, and opportunities via our proposed cores targeting young as well as established investigators to promote and sponsor diverse areas of nonmalignant hematology research at the highest levels.

项目摘要 印第安纳州大学（IU）血液学卓越合作中心（CCEH）的中心主题是 在造血干细胞（HSC）水平上调节非恶性人类和小鼠造血， 祖细胞（HPC）、细胞因子、趋化因子、生长因子和微环境。这是焦点 在上一个供资期内，我们继续追求这一重大目标，因为我们认识到， 在这些领域，还有更多的东西需要严格界定。成员调查的目标 该中心的目的是利用造血系统的不同组成部分， 基于HSC/HPC的疗法的临床效用和功效。治疗遗传性骨髓疾病- 衍生细胞可以通过细胞和遗传方法获得， 和失调然而，要成功地应用这些模式，就需要更深入地了解 细胞、分子、生物化学HSC和HPC调节以及影响它们的造血参数 在移植中的有效使用，如归巢，细胞周期调节，自我更新，表观遗传学，以及 造血生态位。拟议的国际环境卫生联合会汇集了25个成员的积极参与， 都得到了国家卫生研究院国防部或退伍军人事务部的资助这些调查人员与各种各样的人进行高度互动， 造血和HSC生物学以及其他直接影响或 间接影响造血系统的多个组成部分。IU-CCEH建议设立3个 生物医学研究核心集中在带来最先进的技术，推进的工作， 该中心的成员，全国其他类似的CCEH中心，以及全国合格的调查人员 不属于任何NIDDK资助的CCEH。此外，IU-CCEH将有一个浓缩方案， 核心任务是为对非恶性肿瘤感兴趣的年轻和未来科学家建立培训计划 血液学研究该联合会的具体目标是：1）建立、运作和管理三个重要的 生物医学核心为IUSM的研究人员和IUSM以外的其他研究人员提供基本服务， 参与HSC/HPC生物学的最高质量的非恶性基础和临床研究。2)建立， 经营和管理一个丰富的计划，以支持，促进和加强青年的研究 非恶性HSC调控和HSC临床应用领域的研究者。3)积极参与 实施合作伙伴试点和可行性筹资机制， CCEH中心遍布美国。4）协调拟议应用程序核心的财务管理。第五章） 与全国其他CCEH中心密切合作，采取和实施政策，资金 机制和机会，通过我们提出的核心针对年轻人以及建立调查， 在最高水平上促进和赞助非恶性血液学研究的各个领域。